12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Elvitegravir regulatory update

Gilead said EMA accepted for review an MAA for elvitegravir to treat HIV-1 infection in treatment-experienced patients. The company submitted the...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >